These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 34712667)

  • 1. DNA Damage Repair Deficiency in Pancreatic Ductal Adenocarcinoma: Preclinical Models and Clinical Perspectives.
    Stoof J; Harrold E; Mariottino S; Lowery MA; Walsh N
    Front Cell Dev Biol; 2021; 9():749490. PubMed ID: 34712667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
    Shui L; Li X; Peng Y; Tian J; Li S; He D; Li A; Tian B; Li M; Gao H; An N; Yi C; Cao D
    J Transl Med; 2021 Jul; 19(1):301. PubMed ID: 34247626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting DNA damage repair pathways in pancreas cancer.
    Crowley F; Park W; O'Reilly EM
    Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olaparib Monotherapy for Previously Treated Pancreatic Cancer With DNA Damage Repair Genetic Alterations Other Than Germline BRCA Variants: Findings From 2 Phase 2 Nonrandomized Clinical Trials.
    Javle M; Shacham-Shmueli E; Xiao L; Varadhachary G; Halpern N; Fogelman D; Boursi B; Uruba S; Margalit O; Wolff RA; Golan T
    JAMA Oncol; 2021 May; 7(5):693-699. PubMed ID: 33662100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical models of pancreatic ductal adenocarcinoma.
    Krempley BD; Yu KH
    Chin Clin Oncol; 2017 Jun; 6(3):25. PubMed ID: 28705002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-Derived Xenograft Models of Pancreatic Cancer: Overview and Comparison with Other Types of Models.
    Garcia PL; Miller AL; Yoon KJ
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32456018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling human pancreatic ductal adenocarcinoma for translational research: current options, challenges, and prospective directions.
    Suri R; Zimmerman JW; Burkhart RA
    Ann Pancreat Cancer; 2020 Dec; 3():. PubMed ID: 33889840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.
    Zhou T; Xie Y; Hou X; Bai W; Li X; Liu Z; Man Q; Sun J; Fu D; Yan J; Zhang Z; Wang Y; Wang H; Jiang W; Gao S; Zhao T; Chang A; Wang X; Sun H; Zhang X; Yang S; Huang C; Hao J; Liu J
    J Exp Clin Cancer Res; 2023 May; 42(1):111. PubMed ID: 37143164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translating complexity and heterogeneity of pancreatic tumor: 3D in vitro to in vivo models.
    Heinrich MA; Mostafa AMRH; Morton JP; Hawinkels LJAC; Prakash J
    Adv Drug Deliv Rev; 2021 Jul; 174():265-293. PubMed ID: 33895214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies.
    Restifo D; McDermott JR; Cvetkovic D; Dos Santos T; Ogier C; Surumbayeva A; Handorf EA; Schimke C; Ma C; Cai KQ; Olszanski AJ; Kathad U; Bhatia K; Sharma P; Kulkarni A; Astsaturov I
    Mol Cancer Ther; 2023 Oct; 22(10):1182-1190. PubMed ID: 37552607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    Sehdev A; Gbolahan O; Hancock BA; Stanley M; Shahda S; Wan J; Wu HH; Radovich M; O'Neil BH
    Clin Cancer Res; 2018 Dec; 24(24):6204-6211. PubMed ID: 30131383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy.
    Gong M; Meng H; Tan D; Li P; Qin J; An Q; Shi C; An J
    Animal Model Exp Med; 2023 Oct; 6(5):409-418. PubMed ID: 37890865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Diverse Applications of Pancreatic Ductal Adenocarcinoma Organoids.
    Low RRJ; Lim WW; Nguyen PM; Lee B; Christie M; Burgess AW; Gibbs P; Grimmond SM; Hollande F; Putoczki TL
    Cancers (Basel); 2021 Oct; 13(19):. PubMed ID: 34638463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting DNA Damage Repair Mechanisms in Pancreas Cancer.
    Perkhofer L; Golan T; Cuyle PJ; Matysiak-Budnik T; Van Laethem JL; Macarulla T; Cauchin E; Kleger A; Beutel AK; Gout J; Stenzinger A; Van Cutsem E; Bellmunt J; Hammel P; O'Reilly EM; Seufferlein T
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.
    Perkhofer L; Gout J; Roger E; Kude de Almeida F; Baptista Simões C; Wiesmüller L; Seufferlein T; Kleger A
    Gut; 2021 Mar; 70(3):606-617. PubMed ID: 32855305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer.
    Dreyer SB; Upstill-Goddard R; Paulus-Hock V; Paris C; Lampraki EM; Dray E; Serrels B; Caligiuri G; Rebus S; Plenker D; Galluzzo Z; Brunton H; Cunningham R; Tesson M; Nourse C; Bailey UM; Jones M; Moran-Jones K; Wright DW; Duthie F; Oien K; Evers L; McKay CJ; McGregor GA; Gulati A; Brough R; Bajrami I; Pettitt S; Dziubinski ML; Candido J; Balkwill F; Barry ST; Grützmann R; Rahib L; ; ; Johns A; Pajic M; Froeling FEM; Beer P; Musgrove EA; Petersen GM; Ashworth A; Frame MC; Crawford HC; Simeone DM; Lord C; Mukhopadhyay D; Pilarsky C; Tuveson DA; Cooke SL; Jamieson NB; Morton JP; Sansom OJ; Bailey PJ; Biankin AV; Chang DK
    Gastroenterology; 2021 Jan; 160(1):362-377.e13. PubMed ID: 33039466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment opportunities and future perspectives for pancreatic cancer patients with germline BRCA1-2 pathogenic variants.
    Macchini M; Centonze F; Peretti U; Orsi G; Militello AM; Valente MM; Cascinu S; Reni M
    Cancer Treat Rev; 2021 Nov; 100():102262. PubMed ID: 34418781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived tumor xenograft and organoid models established from resected pancreatic, duodenal and biliary cancers.
    Pham NA; Radulovich N; Ibrahimov E; Martins-Filho SN; Li Q; Pintilie M; Weiss J; Raghavan V; Cabanero M; Denroche RE; Wilson JM; Metran-Nascente C; Borgida A; Hutchinson S; Dodd A; Begora M; Chadwick D; Serra S; Knox JJ; Gallinger S; Hedley DW; Muthuswamy L; Tsao MS
    Sci Rep; 2021 May; 11(1):10619. PubMed ID: 34011980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
    Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
    Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.